Synthetic Supercoiled Circular DNA Assembly Without Bacterial Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing circular DNA devoid of bacterial DNA sequences are complex and time-consuming, limiting the scalability and efficiency of gene therapy applications, and existing non-viral delivery methods face challenges such as immune responses and high production costs.
Innovation Solution
A method using heteroduplex thermostable ligase assembly (HTLA) to create synthetic circular supercoiled DNA (SCSDNA) by denaturing and annealing precursor DNA fragments in the presence of thermostable DNA ligase, optionally with type II topoisomerase, to generate defined sequences without bacterial DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional methods are used to produce circular DNA devoid of bacterial DNA sequences, then the DNA can be used for gene therapy, but the production process is complex and time-consuming
Solution Approach 1:
The patent employs heteroduplex thermostable ligase assembly (HTLA), a method that utilizes thermostable DNA ligase enzymes to join DNA fragments at elevated temperatures. This parameter change in reaction conditions enables efficient ligation while producing circular DNA devoid of bacterial sequences, significantly reducing production time from weeks to days while maintaining high purity
Solution Approach 2:
The patent replaces traditional mechanical purification methods with enzymatic assembly processes. By using thermostable ligase and type II topoisomerase enzymes to directly assemble and circularize DNA fragments in vitro, the method eliminates complex mechanical purification steps required by traditional bacterial transformation methods
2Ease of manufacture
If plasmids are used for non-viral gene delivery, then production is simpler, but bacterial DNA sequences elicit patient immune response
Solution Approach 1:
The patent extracts and removes all bacterial DNA sequences from the plasmid structure, retaining only the essential eukaryotic regulatory elements (promoters, enhancers, polyadenylation signals) and the therapeutic gene. This creates minicircle DNA that is completely devoid of bacterial origin, eliminating immune recognition while maintaining gene expression capability
Solution Approach 2:
The patent segments the plasmid into essential functional elements (therapeutic gene, regulatory sequences) and non-essential bacterial elements (origin of replication, antibiotic resistance genes). Only the essential segments are retained in the final minicircle construct, creating a streamlined DNA molecule free of immunogenic bacterial sequences
3Manufacturing precision
If minicircles are produced by engineered recombination in bacterial cells, then bacterial DNA is removed, but the production process is highly complex and time-consuming
Solution Approach 1:
The patent uses thermostable DNA ligase and type II topoisomerase as intermediary enzymes to facilitate DNA assembly and circularization in vitro. These enzymes mediate the joining of DNA fragments and the introduction of supercoils, eliminating the need for complex bacterial recombination systems while achieving complete removal of bacterial DNA sequences
Solution Approach 2:
The patent replaces the complex bacterial cellular machinery required for recombination with in vitro enzymatic systems. By using purified thermostable ligase and topoisomerase enzymes in controlled buffer conditions, the method simplifies the production process from months to days while maintaining complete removal of bacterial DNA
4Loss of time
If enzymatic production of minicircle-like DNA is performed in test tube, then production time is reduced, but GMP production remains highly problematic
Solution Approach 1:
The patent uses thermostable enzymes that function optimally at elevated temperatures (60-95°C), which denatures most contaminating proteins and simplifies downstream purification. This parameter change in reaction temperature enables the process to be conducted in a single test tube without complex GMP facilities, reducing production time while improving manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates the production of scalable, efficient, and durable synthetic circular supercoiled DNA, enhancing gene delivery efficiency and reducing production time and immune response issues.
Implementation Method 1
a thermostable DNA ligase, wherein the thermostable DNA ligase joins the at least two precursor fragments to each other to form a covalently closed circular structure
Implementation Method 2
a type II topoisomerase, wherein the type II topoisomerase introduces supercoils into the covalently closed circular structure
Implementation Method 3
A method using heteroduplex thermostable ligase assembly (HTLA) to create synthetic circular supercoiled DNA (SCSDNA) by denaturing and annealing precursor DNA fragments
Data Source
AI summary
Current minicircle production methods are slow, expensive, and difficult to perform under GMP conditions because, in most cases, the product is derived from bacteria. In contrast, HTLA-and CHTLA-based synthetic circular supercoiled DNA production can be done completely in a test tube, using chemically or enzymatically synthesized oligonucleotides, long single stranded DNA, and/or double stranded DNA.